Innoviva, Inc. (INVA) stock
INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3037% below fair value
$18.41+0.00 (0.00%)
Close on Nov 20, 2026Market cap $1.33BP/E 9.3Yield –
Innoviva gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Innoviva's gross profit for the twelve months ending Sep 30, 2026 was $326.50M, up 5.3% year over year. For fiscal 2025 it was $307.67M, up 3.9% from the year before.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $307.67M | +3.9% |
| FY2024 | Dec 31, 2024 | $296.21M | +20.4% |
| FY2023 | Dec 31, 2023 | $246.04M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $84.38M | +11.7% |
| Q2 FY2026 | Jun 30, 2026 | $90.62M | +9.0% |
| Q1 FY2026 | Mar 31, 2026 | $75.83M | +3.4% |
| Q4 FY2025 | Dec 31, 2025 | $75.67M | -3.2% |
| Q3 FY2025 | Sep 30, 2025 | $75.54M | +3.5% |
| Q2 FY2025 | Jun 30, 2025 | $83.15M | -2.2% |
| Q1 FY2025 | Mar 31, 2025 | $73.32M | +22.0% |
| Q4 FY2024 | Dec 31, 2024 | $78.13M | – |
| Q3 FY2024 | Sep 30, 2024 | $73.01M | – |
| Q2 FY2024 | Jun 30, 2024 | $84.99M | – |
| Q1 FY2024 | Mar 31, 2024 | $60.09M | – |
See a number that looks wrong?